(1550584) A high proportion of IGHV4-39, subset#8 and #8B in Chinese patients with chronic lymphocytic leukemia: a retrospective analysis of 3154 Ig VH sequences by cwCLL, Chinese workshop on CLL

Primary Author; Presenting Author(s)

• 

  Yi Xia, MD

  Attending Physician, Department of Hematology
  the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)

  Slides

Co-Author(s)

• TQ

  Tonglu Qiu, Dr

  Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)
• SY

  Shuhua Yi, Dr

  State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
  Tianjin, China (People's Republic)
• CQ

  Chun Qiao, Dr

  Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)
• 

  Huayuan Zhu, MD

  the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)
• 

  Yuting Yan, Dr

  State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
  Tianjin, China (People's Republic)
• LY

  Li Yao, Dr

  Department of Hematology, First Affiliated Hospital of Soochow University, Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases
  Suzhou, China (People's Republic)
• MZ

  Mingqing Zhu, Dr

  Department of Hematology, First Affiliated Hospital of Soochow University, Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases
  Suzhou, China (People's Republic)
• HP

  Hongling Peng, Dr

  Department of Hematology, The Second Xiangya Hospital, Central South University
  Changsha, China (People's Republic)
• 

  Heng Li, MD

  Department of Hematology, The Second Xiangya Hospital, Central South University
  Changsha, China (People's Republic)
• LH

  Liang Huang, Dr

  Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, China (People's Republic)
• MX

  Min Xiao, Dr

  Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, China (People's Republic)
• JJ

  Jie Jin, Dr

  Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, China (People's Republic)
• JM

  Jianqing Mi, Dr

  Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China (People's Republic)
• JZ

  Jiaojiao Zhang, Dr

  Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China (People's Republic)
• SW

  Shaoyuan Wang, Dr

  Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital
  Fuzhou, China (People's Republic)
• ZZ

  Zhengjin Zheng, Dr

  Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital
  Fuzhou, China (People's Republic)
• BL

  Bingzong Li, Dr

  Department of Hematology, The Second Affiliated Hospital of Soochow University
  Suzhou, China (People's Republic)
• HZ

  Han Zhang, Dr

  Department of Hematology, The Second Affiliated Hospital of Soochow University
  Suzhou, China (People's Republic)
• 

  Wei Xu, MD, PhD

  Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)
• 

  Lugui Qiu, MD

  Professor & Director, Department of Lymphoma & Myeloma
  Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
  Tianjin, China (People's Republic)
• JL

  Jianyong Li, MD, PhD

  Chief of Hematology department
  Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, China (People's Republic)